The DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
Abstract
Hyperthyroidism is a common condition with a global prevalence of 0·2-1·3%. When clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg, low TSH, high free thyroxine [FT4], or high free tri-iodothyonine [FT3]). If hyperthyroidism is confirmed by biochemical tests, a nosological diagnosis should be done to find out which disease is causing the hyperthyroidism. Helpful tools are TSH-receptor antibodies, thyroid peroxidase antibodies, thyroid ultrasonography, and scintigraphy. Hyperthyroidism is mostly caused by Graves' hyperthyroidism (70%) or toxic nodular goitre (16%). Hyperthyroidism can also be caused by subacute granulomatous thyroiditis (3%) and drugs (9%) such as amiodarone, tyrosine kinase inhibitors, and immune checkpoint inhibitors. Disease-specific recommendations are given. Currently, Graves' hyperthyroidism is preferably treated with antithyroid drugs. However, recurrence of hyperthyroidism after a 12-18 month course of antithyroid drugs occurs in approximately 50% of patients. Being younger than 40 years, having FT4 concentrations that are 40 pmol/L or higher, having TSH-binding inhibitory immunoglobulins that are higher than 6 U/L, and having a goitre size that is equivalent to or larger than WHO grade 2 before the start of treatment with antithyroid drugs increase risk of recurrence. Long-term treatment with antithyroid drugs (ie, 5-10 years of treatment) is feasible and associated with fewer recurrences (15%) than short-term treatment (ie, 12-18 months of treatment). Toxic nodular goitre is mostly treated with radioiodine (131I) or thyroidectomy and is rarely treated with radiofrequency ablation. Destructive thyrotoxicosis is usually mild and transient, requiring steroids only in severe cases. Specific attention is given to patients with hyperthyroidism who are pregnant, have COVID-19, or have other complications (eg, atrial fibrillation, thyrotoxic periodic paralysis, and thyroid storm). Hyperthyroidism is associated with increased mortality. Prognosis might be improved by rapid and sustained control of hyperthyroidism. Innovative new treatments are expected for Graves' disease, by targeting B cells or TSH receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third, the proximal predominant weakness with greater functional impairment in the upper extremities (2/5 proximally) on formal neurological examination differs from the classic lower limb predominant or ascending pattern typically described in TPP, expanding the recognized clinical spectrum of this condition [9].”
From Iatrogenic Thyrotoxicosis and Corticosteroid-Triggered Hypokalemic Periodic Paralysis in a Patient With Treated Hypothyroidism (2026) · cites this paper as [9]
Citations
Cites
1 retracted
Rapoport, B., & McLachlan, S. M. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1098 · Cited by 87
RetractedHindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Thyroid hormone and the cardiovascular system.
Klein, I., & Ojamaa, K. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440707 · Cited by 2,300
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Glinoer, D. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0300 · Cited by 1,364
Smith, T. J., & Hegedűs, L. D. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,338
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A. K., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,166
Self-citationBarroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Research works printed but not linked: 1
- Burch, 2021, Chapter 28. Overview of the clinical manifestations of thyrotoxicosis, 419
Cited by
Sorted by citations
Lumsden, M. A., Dekkers, O. M., Faubion, S. S., Hirschberg, A. L., Jayasena, C. N., Lambrinoudaki, I. V., Louwers, Y. V., Pinkerton, J. V., Šojat, A. S., & van Hulsteijn, L. T. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf206 · Cited by 82
Thyroid disorders and gastrointestinal dysmotility: an old association
Xu, G.-M., Hu, M.-X., Li, S.-Y., Ran, X., Zhang, H., & Ding, X.-F. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1389113 · Cited by 43
Kostopoulos, G., & Effraimidis, G. (2024) · European Thyroid Journal · doi:10.1530/etj-23-0254 · Cited by 36
Self-citationRegulatory T Cells in the Pathogenesis of Graves’ Disease
Kuštrimović, N. Z., Gallo, D., Piantanida, E., Bartalena, L., Lai, A., Zerbinati, N., Tanda, M. L., & Mortara, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216432 · Cited by 27
Shu, Q., Kang, C., Li, J., Hou, Z., Xiong, M., Wang, X., & Peng, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296733 · Cited by 25
Metadata
- Authors
- Wiersinga, W. M., Poppe, K. G., & Effraimidis, G.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Université Libre de Bruxelles (BE)
- University of Thessaly (GR)
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2023-04
- Volume
- 11
- Issue
- 4
- Pages
- 282-298
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4321766463
- Semantic Scholar
- f3b4164bc2bb48249a703dd0658e104ae5a4fcfb
- Cited by
- 254
- References
- 154
- Citations by year
- 2026: 76 · 2025: 85 · 2024: 75 · 2023: 18
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- hyperthyroidism, Graves' disease, etiology, pathogenesis, diagnosis, antithyroid drug therapy, thyroidectomy, radiofrequency ablation, thyrotoxicosis, thyroid storm, thyrotoxic periodic paralysis, atrial fibrillation, pregnancy, COVID-19 pandemic, prognosis, mortality, B cell-targeted therapy
- MeSH terms
- COVID-19, COVID-19 Testing, Female, Goiter, Nodular, Graves Disease, Humans, Hyperthyroidism, Iodine Radioisotopes, Pregnancy, Prognosis, Antithyroid Agents, Thyrotropin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review